iShares Core MSCI Emerging Markets ETF vs Revolution Medicines Inc. Common Stock — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.35 (market cap $162.00B), while Revolution Medicines Inc. Common Stock trades at $189.32 (market cap $40.32B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 4× Revolution Medicines Inc. Common Stock's market cap, and iShares Core MSCI Emerging Markets ETF is more actively traded (13,446,151 versus 4,855,734). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| IEMG | RVMD | |
|---|---|---|
Market Cap | $162.00B | $40.32B |
Volume | 13,446,151 | 4,855,734 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $221.15 |
52-Week Low | $64.22 | $47.50 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $37.02B |
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $81.40, down 0.78% with bearish technical signals from moving averages while oscillators remain neutral. The emerging markets ETF has demonstrated strong performance with 35% returns over the past year according to recent analysis, though faces competition from lower-cost alternatives. Recent news highlights emerging markets attracting record capital flows as investors diversify beyond US mega-cap technology stocks.
The outlook remains cautiously optimistic given emerging markets' recent outperformance and dollar weakness, though higher expense ratios compared to competitors and concentration in technology sectors present risks. Technical indicators suggest near-term pressure with support at $79-80 levels, while fundamental strength in emerging market growth supports longer-term potential.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →